Parag Parikh Flexi Cap Fund Increased Stake in This Pharma Company; Board to Consider Share Buyback Proposal

The Indian equity markets ended marginally higher on Wednesday, with the benchmark Nifty 50 index closing up 0.14 per cent at 23,412.60. Positive sentiment across broader markets supported stock-specific action in pharmaceutical counters. In this segment, shares of Zydus Lifesciences remained in focus after the company announced that its board will consider a share buyback proposal in the upcoming board meeting. On Wednesday, Zydus Lifesciences share price ended 0.92 per cent higher at Rs 939.25.

Zydus Lifesciences to Consider Share Buyback

Zydus Lifesciences informed exchanges that the Board of Directors in its meeting scheduled on May 19, 2026 will consider a proposal for buyback of fully paid-up equity shares of the company along with matters necessary and incidental thereto.

The company stated that the proposed buyback will be considered in accordance with applicable provisions under the Companies Act, 2013 and SEBI (Buy-back of Securities) Regulations, 2018, along with other applicable laws.

Earlier, the company had already informed exchanges regarding the board meeting scheduled on May 19, 2026 for approval of Q4FY26 and FY26 financial results. The buyback proposal will now also be considered during the same meeting.

The company further stated that the trading window for directors and designated persons will remain closed till May 21, 2026 and will reopen from May 22, 2026 in accordance with insider trading regulations.

Zydus Lifesciences Shareholding Performance

As per the March 2026 quarter shareholding pattern, promoter holding in Zydus Lifesciences remained unchanged at 75.00 per cent compared to the December 2025 quarter. Foreign Institutional Investors (FIIs) reduced their stake marginally to 6.95 per cent from 7.06 per cent in the previous quarter, while Domestic Institutional Investors (DIIs) increased their holding to 11.20 per cent from 11.08 per cent sequentially. Public shareholding remained stable at 6.86 per cent during the quarter.

Meanwhile, Parag Parikh Flexi Cap Fund increased its stake in the company to 1.96 per cent in Q4FY26 from 1.86 per cent held in Q3FY26.

About Zydus Lifesciences

Zydus Lifesciences is a global pharmaceutical company engaged in the discovery, development, manufacturing and marketing of healthcare therapies across multiple therapeutic segments. The company has operations across formulations, biologics, vaccines, active pharmaceutical ingredients and consumer wellness products.

The company has a presence across India, the United States, Europe and emerging markets with manufacturing facilities and research centres focused on innovation-driven healthcare solutions.

Share your views on Zydus Lifesciences’ proposed share buyback in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.